Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma
Details : The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American, Central American and Caribbean countries, which are part of Takeda’s Growth & Emerging Markets Business U...
Brand Name : Neosaldina
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 29, 2021
Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
Details : The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Business Unit.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 02, 2020
Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?